Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Administrative Data Can Identify PH to Aid in Disease Research

Hospital-based administrative data can be used to identify patients with pulmonary hypertension (PH) in medical records, according to a study done in Canada. These results, if validated, would pave the way for advances in the screening and treatment of PH, and help investigators improve epidemiological research into this rare…

Pulmonary Hypertension Tied to Increased Cancer Risk

People with pulmonary hypertension are at increased risk of developing cancer, especially lung and skin cancers, a new study indicates. The study, “Pulmonary hypertension is associated with an increased incidence of cancer diagnoses,” was published in the journal Pulmonary Circulation. Pulmonary hypertension (PH) refers to…

Tenax Plans Phase 3 Trial of TNX-201 for Later This Year

Tenax Therapeutics has completed a pharmacological assessment of TNX-201, the company’s new oral formulation of imatinib for pulmonary arterial hypertension (PAH), in healthy volunteers. The assessment included comparisons against Gleevec, another oral formulation of imatinib sold by Novartis that is approved to treat certain blood cancers, but was…

Top 10 Pulmonary Hypertension Stories of 2021

Pulmonary Hypertension News brought you the latest coverage of advances in treatment, clinical trials, and scientific research related to pulmonary hypertension (PH) throughout 2021. We look forward to continuing to report more news to patients, family members, and caregivers dealing with PH in the new year. Here are the…

Specialty Care Can Lower Need for Hospitalization With PH-HFpEF

Care at a specialty center is tied to a lower risk of hospitalization for people with heart failure with preserved ejection fraction (HFpEF) who have pulmonary hypertension, according to a new study. The study, “Improved Hospitalization Rates in a Specialty Center for Heart Failure with Preserved Ejection Fraction…


A Conversation With Rare Disease Advocates